Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

• Status: Recruiting
• Trial end date: 2024-07-31
• Target enrollment: 0
• Participant gender: Female

Summary

Resveratrol is a natural plant antitoxin widely found in grapes, mulberries, and other plants. Resveratrol mediates a variety of pharmacological effects, including antioxidant, immunomodulatory, anti-inflammatory, and anti-apoptotic, and plays a protective and therapeutic role in the development of several ROS-related diseases, including POI/POF.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Affiliated Hospital of Nantong University
• Treatments: Resveratrol; Tocopherols; Vitamin E

Criteria

Inclusion Criteria:

1. Amenorrhea or oligomenorrhea at least 4 months and two (>4 weeks interval) basal FSH≥10mIU/ml；

2. The women aged <40 years old；

3. Informed consent, voluntary experiment.

Exclusion Criteria:

1. Pregnant and lactating patients;

2. Patients with endometriosis, adenomyosis, endometrial lesions (submucosal fibroids, endometrial polyps, etc.), uterine fibroids>4 cm or hysterectomy;

3. Patients with adrenal cortical hyperplasia or tumour；

4. Ovarian neoplasms patients；

5. Hydrosalpinx patients；

6. Hyperprolactinemia patients；

7. Patients who are participating in other clinical trials or have participated in other clinical trials within the past three months;

8. Patients with a suspected or real history of alcohol and drug abuse;

9. Known allergy to the investigational drug or its components;

10. Other patients were deemed unsuitable for participation in this trial by the investigator.